Cadre of gene-edit­ing biotechs ral­ly against al­ter­ing DNA that could af­fect fu­ture gen­er­a­tions

A con­tin­gent of biotechs have joined the clar­i­on call against germline gene edit­ing, cit­ing un­re­solved safe­ty, eth­i­cal, le­gal and so­ci­etal is­sues in this type of re­search.

Thir­teen com­pa­nies, col­lec­tive­ly rep­re­sent­ing the Al­liance for Re­gen­er­a­tive Med­i­cine, on Tues­day put out a state­ment of prin­ci­ples that said while edit­ing of dis­ease-caus­ing DNA with­in the body’s non-re­pro­duc­tive (so­mat­ic) cells should pro­ceed, edit­ing germline cells for hu­man tri­als should be off-lim­its, sub­ject for more dis­cus­sion on the in­ter­na­tion­al stage.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.